Growth Hormone Deficiency
Conditions
Keywords
growth hormone deficiency, circadian variation
Brief summary
This is an exploratory trial with four cross-over arms measuring the pharmacokinetic and pharmacodynamic profiles of growth hormone using two different modes of growth hormone administration (subcutaneous infusion into the abdomen or subcutaneous bolus injection in the thigh) in 8 adult male or female patients with growth hormone deficiency during interval exercise or in supine rest. The order of dosing regimen within the groups and between the groups will be randomised. All patients will go through four different treatment sessions:A/B Single subcutaneous bolus injection, supine rest without/with interval exercise, sessions C/D: Continuous subcutaneous infusion, supine rest without/with interval exercise. Hypotheses: 1) There is day-to-day variation of exogenous growth hormone, 2)Concentration of growth hormone decreases due to exercise compared to supine rest, 3)There is a circadian variation in pharmacokinetics of exogenous growth hormone infused subcutaneously
Detailed description
The subjects will attend a screening visit and four treatment sessions. The dosing visits will comprise either 2-day hospital stay for the bolus injection group or 3 day hospital stay for the infusion group.
Interventions
DRUGNorditropin SimpleXx (growth hormone)
3mg/subject/day over two consecutive days
Sponsors
Novo Nordisk A/S
Aarhus University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* AGHD male or female subjects * Stable GH replacement therapy for at least 3 months * Body Mass Index 18,5 to 35.0 kg/m2 * Achieved final height * Age ≥ 18 years
Exclusion criteria
* Known or suspected allergy to trial product or components of the trial product * Subjects with active malignancy * Severe cardiac insufficiency classified according to NYHA III-IV * Unstable angina pectoris, acute myocardial infarction within the last 12 months * Severe, uncontrolled hypertension: sitting blood pressure \> 180/110 mmHg * HbA1C \> 7,5 % * Impaired kidney function: plasma creatinine ≥ 150 umol/l according to the hospital lab. * Impaired liver function: liver parameters exceed 2 times or more the upper normal limit, according to the hospital lab. * Patients on insulin treatment * Stable pituitary replacement therapy for less than 3 months * Participation in any other clinical trial involving any investigational products within the last three months prior to this trial * Any diseases judged by the investigator that could affect the trial * Women of fertile age, who are pregnant, planning to become pregnant or breast-feeding. Women of fertile age, who are not currently using adequate contraception methods such as: contraceptive pills, IUD or who had not undergone hysterectomy or sterilization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic profiles of growth hormone | 48 hours | Pharmacokinetic profiles of growth hormone administrated subcutaneously (3 mg/day) as a bolus in the adult patients with growth hormone deficiency during interval exercise or in supine rest. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic profiles of growth hormone | 60 hours | To compare pharmacokinetic profiles of growth hormone administrated subcutaneously (3 mg/day) as an infusion in the adult patients with growth hormone deficiency during interval exercise or in supine rest. |
Countries
Denmark
Outcome results
None listed